MA39163B1 - Forme cristalline de (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone et utilisation de celle-ci en tant qu'antagonistes des recepteurs de l'orexine - Google Patents

Forme cristalline de (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone et utilisation de celle-ci en tant qu'antagonistes des recepteurs de l'orexine

Info

Publication number
MA39163B1
MA39163B1 MA39163A MA39163A MA39163B1 MA 39163 B1 MA39163 B1 MA 39163B1 MA 39163 A MA39163 A MA 39163A MA 39163 A MA39163 A MA 39163A MA 39163 B1 MA39163 B1 MA 39163B1
Authority
MA
Morocco
Prior art keywords
methylpyrrolidin
methanone
triazol
imidazol
benzo
Prior art date
Application number
MA39163A
Other languages
English (en)
Other versions
MA39163A1 (fr
Inventor
Christoph Boss
Christine Brotschi
Bibia Heidmann
Thierry Sifferlen
Markus Gude
Jodi Williams
Raumer Markus Von
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of MA39163A1 publication Critical patent/MA39163A1/fr
Publication of MA39163B1 publication Critical patent/MA39163B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne des formes cristallines de (s)-(2-(6-chloro-7-méthyl-1h-benzo[d]imidazol-2- yl)-2-méthylpyrrolidin-1-yl)(5-méthoxy-2-(2h-1,2,3-triazol-2-yl)phényl)méthanone, des procédés de préparation de celles-ci, des compositions pharmaceutiques contenant de telles formes cristallines, des compositions pharmaceutiques préparées à partir de telles formes cristallines ainsi que leur utilisation en tant que médicament, notamment en tant qu'antagonistes des récepteurs de l'orexine.
MA39163A 2013-12-03 2014-12-02 Forme cristalline de (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone et utilisation de celle-ci en tant qu'antagonistes des recepteurs de l'orexine MA39163B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2013060596 2013-12-03
PCT/IB2014/066508 WO2015083070A1 (fr) 2013-12-03 2014-12-02 Forme cristalline de (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone et utilisation de celle-ci en tant qu'antagonistes des recepteurs de l'orexine

Publications (2)

Publication Number Publication Date
MA39163A1 MA39163A1 (fr) 2017-11-30
MA39163B1 true MA39163B1 (fr) 2018-09-28

Family

ID=52282786

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39163A MA39163B1 (fr) 2013-12-03 2014-12-02 Forme cristalline de (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone et utilisation de celle-ci en tant qu'antagonistes des recepteurs de l'orexine

Country Status (31)

Country Link
US (1) US9914720B2 (fr)
EP (1) EP3077389B1 (fr)
JP (1) JP6496733B2 (fr)
KR (1) KR102361418B1 (fr)
CN (1) CN105793257B (fr)
AU (1) AU2014358742B2 (fr)
CA (1) CA2929423C (fr)
CL (1) CL2016001342A1 (fr)
CY (1) CY1119695T1 (fr)
DK (1) DK3077389T3 (fr)
EA (1) EA030137B1 (fr)
ES (1) ES2651475T3 (fr)
HK (1) HK1225731B (fr)
HR (1) HRP20171773T1 (fr)
HU (1) HUE035731T2 (fr)
IL (1) IL245923B (fr)
LT (1) LT3077389T (fr)
MA (1) MA39163B1 (fr)
MX (1) MX364208B (fr)
MY (1) MY179862A (fr)
NO (1) NO3077389T3 (fr)
NZ (1) NZ721438A (fr)
PH (1) PH12016500988A1 (fr)
PL (1) PL3077389T3 (fr)
PT (1) PT3077389T (fr)
SA (1) SA516371231B1 (fr)
SI (1) SI3077389T1 (fr)
TW (1) TWI664177B (fr)
UA (1) UA119549C2 (fr)
WO (1) WO2015083070A1 (fr)
ZA (1) ZA201604499B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2617863T3 (es) 2012-06-04 2017-06-20 Actelion Pharmaceuticals Ltd. Derivados de bencimidazol-prolina
UA119151C2 (uk) 2013-12-03 2019-05-10 Ідорсія Фармасьютікалз Лтд КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА
PT3077391T (pt) 2013-12-04 2018-11-26 Idorsia Pharmaceuticals Ltd Utilização de derivados de benzimidazol-prolina
SI3619199T1 (sl) * 2017-05-03 2021-11-30 Idorsia Pharmaceuticals Ltd Priprava derivatov 2-((1,2,3)triazol-2-il)-benzojske kisline
CA3175369A1 (fr) 2020-04-19 2021-10-28 Guy Braunstein Utilisation medicale de daridorexant
JP2024504854A (ja) * 2021-02-02 2024-02-01 メッドシャイン ディスカバリー インコーポレイテッド テトラヒドロピロロ環化合物及びその使用
CN115925699B (zh) * 2022-02-25 2023-10-03 南京知和医药科技有限公司 具有镇痛活性的稠环化合物及其制备方法与用途

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3282927A (en) 1964-05-21 1966-11-01 Bristol Myers Co 5-phenyl-4-thiazolylpenicillins
PT1289955E (pt) 2000-06-16 2005-08-31 Smithkline Beecham Plc Piperidinas para utilizacao como antagonistas dos receptores da orexina
WO2002028839A1 (fr) 2000-10-06 2002-04-11 Neurogen Corporation Derives de benzimidazole et d'indole en tant que modulateurs des recepteurs de la corticoliberine
ATE286897T1 (de) 2000-11-28 2005-01-15 Smithkline Beecham Plc Morpholinderivate als antagonisten an orexinrezeptoren
ATE383359T1 (de) 2001-05-05 2008-01-15 Smithkline Beecham Plc N-aroyl zyklische amine
JP2004534026A (ja) 2001-05-05 2004-11-11 スミスクライン　ビーチャム　パブリック　リミテッド　カンパニー オレキシン受容体アンタゴニストとしてのｎ−アロイルサイクリックアミン誘導体
HUP0400326A2 (hu) * 2001-06-28 2004-09-28 Smithkline Beecham P.L.C. Orexin receptor antagonistákként alkalmazható ciklikus N-(aril-karbonil)-amin-származékok és ezeket tartalmazó gyógyszerkészítmények
GB0115862D0 (en) 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
GB0124463D0 (en) 2001-10-11 2001-12-05 Smithkline Beecham Plc Compounds
GB0127145D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Compounds
GB0130393D0 (en) 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
GB0130335D0 (en) 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
WO2004026866A1 (fr) 2002-09-18 2004-04-01 Glaxo Group Limited Amines cycliques n-aroyle utilisees comme antagonistes du recepteur d'orexine
GB0225944D0 (en) 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
GB0225938D0 (en) 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
GB0225884D0 (en) 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
WO2005118548A1 (fr) 2004-03-01 2005-12-15 Actelion Pharmaceuticals Ltd Derives de 1,2,3,4-tétrahydroisoquinoléine substitués
WO2007105177A1 (fr) 2006-03-15 2007-09-20 Actelion Pharmaceuticals Ltd Dérivés de tétrahydroisoquinoléine pour renforcer la fonction de la mémoire
WO2007135527A2 (fr) * 2006-05-23 2007-11-29 Pfizer Products Inc. Composés de benzimidazolyle
CN101506199A (zh) 2006-08-15 2009-08-12 埃科特莱茵药品有限公司 用作食欲素受体拮抗剂的氮杂环丁烷化合物
KR20090077051A (ko) 2006-09-29 2009-07-14 액테리온 파마슈티칼 리미티드 3-아자-비시클로[3.1.0]헥산 유도체
PE20081229A1 (es) 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
AR064561A1 (es) 2006-12-28 2009-04-08 Actelion Pharmaceuticals Ltd Derivados de 2-aza-biciclo[3.1.0]hexano y su uso en la preparacion de un medicamento para el tratamiento de enfermedades relacionadas con disfunciones generales del sistema de la orexina.
WO2008087611A2 (fr) 2007-01-19 2008-07-24 Actelion Pharmaceuticals Ltd Dérivés de pyrrolidine et de piperidine
CL2008000836A1 (es) 2007-03-26 2008-11-07 Actelion Pharmaceuticals Ltd Compuestos derivados de tiazolidina, antagonistas del receptor de orexina; composicion farmaceutica que los comprende; y su uso en el tratamiento de neurosis emocional, depresion grave, trastornos psicoticos, alzheimer, parkinson, dolor, entre otras.
CA2685743A1 (fr) 2007-05-14 2008-11-20 Actelion Pharmaceuticals Ltd Derives de 2-cyclopropyl-thiazole
EP2150115B1 (fr) 2007-05-23 2013-09-18 Merck Sharp & Dohme Corp. Antagonistes du récepteur de la cyclopropylpyrrolidine orexine
BRPI0813218A2 (pt) 2007-07-03 2014-12-23 Actelion Pharmaceuticals Ltd Composto, composição farmacêutica que o contém como princípio ativo e uso do composto.
GB0712888D0 (en) 2007-07-03 2007-08-15 Glaxo Group Ltd Novel compounds
CA2691638A1 (fr) 2007-07-03 2009-01-08 Glaxo Group Limited Derives de piperidine utiles comme antagonistes vis-avis des recepteurs de l'orexine
KR20100046047A (ko) 2007-07-27 2010-05-04 액테리온 파마슈티칼 리미티드 2-아자-비시클로[3.3.0]옥탄 유도체
DE602008004265D1 (de) 2007-07-27 2011-02-10 Actelion Pharmaceuticals Ltd Trans-3-aza-bicyclo-ä3.1.0ü-hexan-derivate
CN101874030B (zh) 2007-09-24 2012-11-14 埃科特莱茵药品有限公司 用作食欲素受体拮抗剂的吡咯烷和哌啶
PE20091010A1 (es) 2007-10-10 2009-08-08 Actelion Pharmaceuticals Ltd Derivados de tetrahidroquinolina
BRPI0908096A2 (pt) 2008-02-21 2015-08-25 Actelion Pharmaceuticals Ltd Derivado de 2-aza-biciclo [2.2.1] heptano
GB0806536D0 (en) 2008-04-10 2008-05-14 Glaxo Group Ltd Novel compounds
CN102083827A (zh) 2008-07-07 2011-06-01 埃科特莱茵药品有限公司 作为食欲素受体拮抗剂的噻唑烷化合物
WO2010038200A1 (fr) 2008-10-01 2010-04-08 Actelion Pharmaceuticals Ltd Composés d'oxazolidine utilisables en tant qu'antagonistes des récepteurs à orexine
WO2010060471A1 (fr) 2008-11-26 2010-06-03 Glaxo Group Limited Dérivés de la pipéridine utiles en tant qu’antagonistes du récepteur de l’orexine
EP2358713A1 (fr) 2008-11-26 2011-08-24 Glaxo Group Limited Dérivés de l imidazopyridazine agissant en tant qu antagonistes de l orexine
JP2012509910A (ja) 2008-11-26 2012-04-26 グラクソ グループ リミテッド 新規の化合物
AR074426A1 (es) 2008-12-02 2011-01-19 Glaxo Group Ltd Compuesto de n-(((1s,4s,6s)-3-(2-piridinilcarbonil)3-azabiciclo (4,1.0)hept-4-il) metil)-2-heteroarilamina, su uso para la prepracion de un medicamento para el tratamiento de una enfermedad que requiere un antagonista de un receptor de orexina humana y composicion farmaceutica que lo comprende
CA2745433A1 (fr) 2008-12-02 2010-06-10 Glaxo Group Ltd. Derives de n-{[(1r,4s,6r)-3-(2-pyridinylcarbonyl)-3-azabicyclo[4.1.0]hept-4-yl]methyl}-2-heteroarylamine et leurs utilisations
GB0823467D0 (en) * 2008-12-23 2009-01-28 Glaxo Group Ltd Novel Compounds
SG175026A1 (en) 2009-04-24 2011-11-28 Glaxo Group Ltd 3 -azabicyclo [4.1.0] heptanes used as orexin antagonists
WO2012025877A1 (fr) 2010-08-24 2012-03-01 Actelion Pharmaceuticals Ltd Dérivés de proline sulfonamide comme antagonistes des récepteurs de l'orexine
CA2815179A1 (fr) 2010-11-10 2012-05-18 Actelion Pharmaceuticals Ltd Derives de lactame utiles en tant qu'antagonistes du recepteur de l'orexine
ES2541531T3 (es) 2011-02-18 2015-07-21 Actelion Pharmaceuticals Ltd. Nuevos derivados de pirazol e imidazol útiles como antagonistas de orexina
MX343837B (es) 2011-11-08 2016-11-24 Actelion Pharmaceuticals Ltd Derivados de 2 - (1,2,3 -triazol - 2 - il) benzamida y 3 - (1,2,3 - triazol - 2 - il) picolinamida.
ES2617863T3 (es) * 2012-06-04 2017-06-20 Actelion Pharmaceuticals Ltd. Derivados de bencimidazol-prolina
EP2906553B1 (fr) 2012-10-10 2019-06-26 Idorsia Pharmaceuticals Ltd Antagonistes des récepteurs de l'orexine, qui sont des dérivés [ortho bi (hetero )aryl]-[2-(meta bi (hetero)aryl)-pyrrolidin-1-yl]-methanone
EP2970241A1 (fr) 2013-03-12 2016-01-20 Actelion Pharmaceuticals Ltd. Dérivés d'amide d'azétidine en tant qu'antagonistes des récepteurs d'oréxine
UA119151C2 (uk) 2013-12-03 2019-05-10 Ідорсія Фармасьютікалз Лтд КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА
PT3077391T (pt) 2013-12-04 2018-11-26 Idorsia Pharmaceuticals Ltd Utilização de derivados de benzimidazol-prolina

Also Published As

Publication number Publication date
CY1119695T1 (el) 2018-04-04
MX364208B (es) 2019-04-16
EA201600435A1 (ru) 2016-11-30
BR112016012628A8 (pt) 2017-12-26
NZ721438A (en) 2021-12-24
JP6496733B2 (ja) 2019-04-03
PT3077389T (pt) 2017-12-15
CN105793257B (zh) 2018-11-13
CN105793257A (zh) 2016-07-20
MA39163A1 (fr) 2017-11-30
DK3077389T3 (da) 2017-11-13
KR20160092015A (ko) 2016-08-03
NO3077389T3 (fr) 2018-02-10
PH12016500988B1 (en) 2016-06-20
HUE035731T2 (hu) 2018-05-28
KR102361418B1 (ko) 2022-02-09
HK1225731B (zh) 2017-09-15
EA030137B1 (ru) 2018-06-29
ZA201604499B (en) 2019-04-24
IL245923B (en) 2019-09-26
EP3077389B1 (fr) 2017-09-13
US9914720B2 (en) 2018-03-13
TWI664177B (zh) 2019-07-01
EP3077389A1 (fr) 2016-10-12
AU2014358742B2 (en) 2019-02-07
WO2015083070A1 (fr) 2015-06-11
JP2016539136A (ja) 2016-12-15
ES2651475T3 (es) 2018-01-26
CL2016001342A1 (es) 2016-11-18
MX2016007215A (es) 2016-09-07
AU2014358742A1 (en) 2016-07-07
UA119549C2 (uk) 2019-07-10
SI3077389T1 (en) 2018-01-31
CA2929423C (fr) 2021-12-07
MY179862A (en) 2020-11-18
US20160368901A1 (en) 2016-12-22
LT3077389T (lt) 2017-12-11
PH12016500988A1 (en) 2016-06-20
BR112016012628A2 (fr) 2017-08-22
TW201605838A (zh) 2016-02-16
PL3077389T3 (pl) 2018-03-30
SA516371231B1 (ar) 2018-02-20
HRP20171773T1 (hr) 2017-12-29
IL245923A0 (en) 2016-08-02
CA2929423A1 (fr) 2015-06-11

Similar Documents

Publication Publication Date Title
MA39163B1 (fr) Forme cristalline de (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone et utilisation de celle-ci en tant qu'antagonistes des recepteurs de l'orexine
MA39164B1 (fr) Forme de sel cristalline de (s)-(2-(6-chloro-7-méthyl-1 h-benzo[d]imidazol- 2-yl)-2-méthylpyrrolidin-1-yl)(5-méthoxy-2-(2h-1,2,3-triazol-2-yl)phényl)méthanone comme antagoniste des récepteurs à l'oréxine
BR112015031903A2 (pt) composto, sal farmaceuticamente aceitável do composto, composição farmacêutica e utilização de um composto
EA200801184A1 (ru) Производные пипередин-4-ил-пиридазин-3-иламина как быстро диссоциирующие антагонисты рецептора дофамина 2
IN2012DN02735A (fr)
IN2012DN02702A (fr)
IN2012DN00754A (fr)
MY163055A (en) Polycyclic antagonists of lysophosphatidic acid receptors
CL2016002238A1 (es) Compuestos derivados de 3-(5-oxo-4,5-dihidro-1h-tetrazol-1-il)-5,6-dihidropiridin-2(1h)-ona sustituidos con tetrazolona, inhibidores de monocilglicerol aciltransferasa 2 (mgat2); composiciones farmacológicas; útiles para tratar la diabetes, hipeglucemia, intolerancia a la glucosa, resistencia a la insulina, hiperinsulinemia, enfermedad al hígado graso no alcohólico, retinopatía, entre otras.
MA33132B1 (fr) Derives pyrazole utilises comme antagonistes du recepteur ccr4
PH12017501424A1 (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
EA201101118A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
UA97826C2 (ru) Быстро диссоциирующие антагонисты рецептора 2 дофамина
MX2010009574A (es) 2-aminoquinolinas.
MA38358A1 (fr) Formulations de composés organiques
MA32224B1 (fr) Derives de (pyrazolyl-carbonyl) imidazolidinone pour le traitement de maladies retrovirales
EA200970553A1 (ru) Пиперидиниламинопиридазины и их применение в качестве быстро диссоциирующих антагонистов рецептора допамина 2
MA39229A1 (fr) Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines
UA101367C2 (en) Normal;heading 1;heading 2;heading 3;HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS